Prevalence and factors associated with suboptimal adherence to dolutegravir-based regimens among people living with HIV in a specialized clinic in Kampala, Uganda. A cross-sectional study.
DOI:
https://doi.org/10.51168/sjhrafrica.v6i9.2067Keywords:
Dolutegravir adherence, Dolutegravir, People living with HIV, ART suboptimal adherenceAbstract
Background: In Uganda, 54% of people living with HIV(PLHIV) on first-line Antiretroviral Therapy (ART) were taking dolutegravir-based regimens. This study aimed to determine the prevalence and factors associated with suboptimal adherence to dolutegravir-based regimens among PLHIV at a specialized clinic in Uganda.
Methods: A cross-sectional study was conducted at a specialized HIV clinic in Kampala, Uganda, from July to August 2022. Quantitative data were collected using questionnaires and data abstraction tools from 366 consecutively sampled and consented PLHIV. Adherence was measured using a modified Morisky Medication Adherence Scale, which consisted of 9 questions. Qualitative data were collected using in-depth interviews among 13 purposively sampled, consented participants. Quantitative data were analysed using modified Poisson regression in STATA 14 to obtain factors associated with suboptimal adherence at the 5% level of significance. Qualitative data were analyzed using thematic analysis in Open Code version 4.03.
Results: The median age of participants was 44 (IQR: 35 to 52), while 64.8% (237/366) were female. The prevalence of suboptimal adherence to dolutegravir-based regimens was 49% (179/366; 95%Confidence Interval (CI): 44, 54). Alcohol consumption (adjusted Prevalence Ratio (aPR): 1.25; 95%CI: 1.012, 1.543), and unemployment (aPR: 1.27; 95%CI: 1.002, 1.609) were associated with a higher likelihood of suboptimal adherence while the lack of social support (aPR: 0.78; 95%CI: 0.619, 0.993), and talking to the doctor in case of a health problem (aPR: 0.44; 95%CI: 0.307, 1.270) were protective against suboptimal adherence, to dolutegravir-based ART regimens. Barriers to dolutegravir adherence included unemployment, lack of social support, alcohol consumption, and inadequate counseling.
Conclusion: Suboptimal adherence to dolutegravir-based ART was high. Alcohol consumption, unemployment, lack of social support, and inadequate counselling influenced dolutegravir adherence.
Recommendations: Start-up projects to address unemployment should be implemented for PLHIV. Dolutegravir-related virological failure resulting from non-adherence in PLHIV should be investigated.
References
UNAIDS. UNAIDS DATA GENEVA, SWITZERLAND: JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS; 2021.
WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2016:480.
Cruciani M, Parisi SG. Dolutegravir-based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. PloS one. 2019;14(9):e0222229-e. https://doi.org/10.1371/journal.pone.0222229
Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability, and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. eClinicalMedicine. 2020;28. https://doi.org/10.1016/j.eclinm.2020.100573
Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, et al. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Res Hum Retroviruses. 2020;36(1):13-8. https://doi.org/10.1089/aid.2019.0171
MOH. Consolidated Guidelines for Prevention and Treatment of HIV and AIDS in Uganda. MOH, 2020 February 2020.
Twimukye A, Laker M, Odongpiny EAL, Ajok F, Onen H, Kalule I, et al. Patient experiences of switching from Efavirenz to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infectious Diseases. 2021;21(1):1154. https://doi.org/10.1186/s12879-021-06851-9
UPHIA. Assessment Report 2016-2017. 2019:253.
McCluskey SM, Pepperrell T, Hill A, Venter WDF, Gupta RK, Siedner MJ. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021;35(Supplement 2):S127-S35. https://doi.org/10.1097/QAD.0000000000003082
Kilapilo MS, Sangeda RZ, Bwire GM, Sambayi GL, Mosha IH, Killewo J. Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir-Based Regimens in Dar es Salaam, Tanzania. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2022;21:23259582221084543. https://doi.org/10.1177/23259582221084543
Cardoso TS, Costa JdO, Reis EA, Silveira MR, Bonolo PdF, Santos SFd, et al. Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens. Cadernos de Saúde Pública. 2019;35:e00115518. https://doi.org/10.1590/0102-311x00115518
Mehari EA, Muche EA, Gonete KA, Shiferaw KB. Treatment Satisfaction and Its Associated Factors of Dolutegravir-Based Regimen in a Resource-Limited Setting. Patient Prefer Adherence. 2021;15:1177-85. https://doi.org/10.2147/PPA.S308571
MOH. Annual Health Sector Performance Report. Ministry of Health: Ministry of Health; 2021.
MOH. The National HIV and AIDS Strategic Plan 2020/21-2024/25. MOH; 2020 August 2020.
Achieng L, Riedel DJ. Dolutegravir Resistance and Failure in a Kenyan Patient. The Journal of Infectious Diseases. 2019;219(1):165-7. https://doi.org/10.1093/infdis/jiy436
Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. https://doi.org/10.1136/bmjopen-2017-016982
MOH. Ministry of Health Strategic Plan 2020/21-2024/25. 2020:188. https://doi.org/10.5860/crln.48.1.21
NPA. Third National Development Plan (NDP III) 2020/21-2024/25. 2020:341.
UPHIA. UGANDA POPULATION-BASED HIV IMPACT ASSESSMENT. 2022.
Achappa B, Madi D, Bhaskaran U, Ramapuram JT, Rao S, Mahalingam S. Adherence to Antiretroviral Therapy Among People Living with HIV. N Am J Med Sci. 2013;5(3):220-3. https://doi.org/10.4103/1947-2714.109196
Castellucci LA, Shaw J, van der Salm K, Erkens P, Le Gal G, Petrcich W, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Research. 2015;136(4):727-31. https://doi.org/10.1016/j.thromres.2015.07.007
Janežič A, Locatelli I, Kos M. Criterion validity of the 8-item Morisky Medication Adherence Scale in patients with asthma. PLoS One. 2017;12(11):e0187835. https://doi.org/10.1371/journal.pone.0187835
UBoS. The Uganda National Household Survey report 2019/2020. 2021.
Mutagonda RF, Mlyuka HJ, Maganda BA, Kamuhabwa AAR. Adherence, Effectiveness, and Safety of Dolutegravir-Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2022;21:23259582221109613. https://doi.org/10.1177/23259582221109613
Hingson RW, Zha W, White AM. Drinking Beyond the Binge Threshold: Predictors, Consequences, and Changes in the U.S. Am J Prev Med. 2017;52(6):717-27. https://doi.org/10.1016/j.amepre.2017.02.014
Adrawa N, Alege JB, Izudi J. Alcohol consumption increases non-adherence to ART among people living with HIV enrolled in the community-based care model in rural northern Uganda. PLOS ONE. 2020;15(11):e0242801. https://doi.org/10.1371/journal.pone.0242801
Campbell L, Masquillier C, Thunnissen E, Ariyo E, Tabana H, Sematlane N, et al. Social and Structural Determinants of Household Support for ART Adherence in Low- and Middle-Income Countries: A Systematic Review Int J Environ Res Public Health. 2020;17(11). https://doi.org/10.3390/ijerph17113808
Ajuna N, Tumusiime B, Amanya J, Awori S, Rukundo GZ, Asiimwe JB. Social Networks and Barriers to ART Adherence Among Young Adults (18-24 years) Living with HIV at Selected Primary Health Facilities of South-Western Uganda: A Qualitative Study. HIV AIDS (Auckland). 2021;13:939-58. https://doi.org/10.2147/HIV.S328643
Stankunas M, Kalediene R, Starkuviene S, Kapustinskiene V. Duration of unemployment and depression: a cross-sectional survey in Lithuania. BMC Public Health. 2006;6(1):174. https://doi.org/10.1186/1471-2458-6-174
Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, et al. Depression and Medication Adherence in the Treatment of Chronic Diseases in the United States: A Meta-Analysis. Journal of General Internal Medicine. 2011;26(10):1175-82. https://doi.org/10.1007/s11606-011-1704-y
Nachega JB, Uthman OA, Peltzer K, Richardson LA, Mills EJ, Amekudzi K, et al. Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis. Bull World Health Organ. 2015;93(1):29-41. https://doi.org/10.2471/BLT.14.138149
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Edith Namakula, Henry Mugerwa, Freddy Eric Kitutu, Aida N Kawuma, Ronald Kiguba, Joan N Kalyango
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
